{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:28:11Z","timestamp":1790810891981,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400328"],"award-info":[{"award-number":["81400328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773795"],"award-info":[{"award-number":["81773795"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013150","name":"Scientific Research and Sharing Platform Construction Project of Shaanxi Province","doi-asserted-by":"publisher","award":["2020PT-003"],"award-info":[{"award-number":["2020PT-003"]}],"id":[{"id":"10.13039\/501100013150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2018SF-266"],"award-info":[{"award-number":["2018SF-266"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017614","name":"Xi'an Medical University","doi-asserted-by":"publisher","award":["2018PT23"],"award-info":[{"award-number":["2018PT23"]}],"id":[{"id":"10.13039\/501100017614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017614","name":"Xi'an Medical University","doi-asserted-by":"publisher","award":["2018XNRC02"],"award-info":[{"award-number":["2018XNRC02"]}],"id":[{"id":"10.13039\/501100017614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vph.2021.106878","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T12:13:32Z","timestamp":1621253612000},"page":"106878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Inducible degrader of LDLR: A potential novel therapeutic target and emerging treatment for hyperlipidemia"],"prefix":"10.1016","volume":"140","author":[{"given":"Qi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vph.2021.106878_bb0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vph.2021.106878_bb0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fphar.2017.00372","article-title":"Statins and new-onset diabetes mellitus: LDL receptor may provide a key link","volume":"8","author":"Yu","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.vph.2021.106878_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.vph.2021.106878_bb0025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MOL.0000000000000718","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition as the next statin?","volume":"31","author":"Rakipovski","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"issue":"5936","key":"10.1016\/j.vph.2021.106878_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1168974","article-title":"LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor","volume":"325","author":"Zelcer","year":"2009","journal-title":"Science"},{"issue":"51","key":"10.1016\/j.vph.2021.106878_bb0035","doi-asserted-by":"crossref","first-page":"36288","DOI":"10.1074\/jbc.274.51.36288","article-title":"MIR is a novel ERM-like protein that interacts with myosin regulatory light chain and inhibits neurite outgrowth","volume":"274","author":"Olsson","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2021.106878_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mehy.2015.11.010","article-title":"IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia","volume":"86","author":"Zhang","year":"2016","journal-title":"Med. Hypotheses"},{"issue":"50","key":"10.1016\/j.vph.2021.106878_bb0045","doi-asserted-by":"crossref","first-page":"20107","DOI":"10.1073\/pnas.1111589108","article-title":"FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors","volume":"108","author":"Calkin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"39","key":"10.1016\/j.vph.2021.106878_bb0050","doi-asserted-by":"crossref","first-page":"13570","DOI":"10.1074\/jbc.RA120.014349","article-title":"Structural analysis of the LDL receptor-interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate-binding site","volume":"295","author":"Martinelli","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.vph.2021.106878_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.vph.2021.106878_bb0060","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1161\/ATVBAHA.112.250571","article-title":"Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis","volume":"32","author":"Zhang","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2021.106878_bb0065","article-title":"SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1","volume":"296","author":"Wang","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.vph.2021.106878_bb0070","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.vph.2021.106878_bb0075","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1101\/gad.2056211","article-title":"The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor","volume":"25","author":"Zhang","year":"2011","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.vph.2021.106878_bb0080","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/CIRCRESAHA.115.307298","article-title":"The deubiquitylase USP2 regulates the LDLR pathway by counteracting the E3-ubiquitin ligase IDOL","volume":"118","author":"Nelson","year":"2016","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.vph.2021.106878_bb0085","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1194\/jlr.M037713","article-title":"The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation","volume":"54","author":"Sorrentino","year":"2013","journal-title":"J. Lipid Res."},{"issue":"11","key":"10.1016\/j.vph.2021.106878_bb0090","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s42255-019-0127-7","article-title":"IDOL regulates systemic energy balance through control of neuronal VLDLR expression","volume":"1","author":"Lee","year":"2019","journal-title":"Nat. Metab."},{"issue":"26","key":"10.1016\/j.vph.2021.106878_bb0095","doi-asserted-by":"crossref","first-page":"19720","DOI":"10.1074\/jbc.M110.123729","article-title":"The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2","volume":"285","author":"Hong","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.vph.2021.106878_bb0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"issue":"1","key":"10.1016\/j.vph.2021.106878_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/cvr\/cvw010","article-title":"Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol","volume":"110","author":"Ibrahim","year":"2016","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.vph.2021.106878_bb0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/CIRCRESAHA.115.304440","article-title":"Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice","volume":"115","author":"Calkin","year":"2014","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.vph.2021.106878_bb0115","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1161\/ATVBAHA.118.311168","article-title":"Inactivation of the E3 ubiquitin ligase IDOL attenuates diet-induced obesity and metabolic dysfunction in mice","volume":"38","author":"van Loon","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.vph.2021.106878_bb0120","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.vph.2021.106878_bb0125","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1161\/ATVBAHA.109.201020","article-title":"Genetic variants influencing circulating lipid levels and risk of coronary artery disease","volume":"30","author":"Waterworth","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7307","key":"10.1016\/j.vph.2021.106878_bb0130","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.vph.2021.106878_bb0135","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FPC.0000000000000089","article-title":"The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia","volume":"24","author":"Santos","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.vph.2021.106878_bb0140","doi-asserted-by":"crossref","first-page":"14280","DOI":"10.1038\/s41598-020-71241-1","article-title":"IDOL gene variant is associated with hyperlipidemia in Han population in Xinjiang, China","volume":"10","author":"Adi","year":"2020","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.vph.2021.106878_bb0145","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1161\/ATVBAHA.119.312589","article-title":"IDOL G51S variant is associated with high blood cholesterol and increases low-density lipoprotein receptor degradation","volume":"39","author":"Adi","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"17","key":"10.1016\/j.vph.2021.106878_bb0150","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/eurheartj\/ehs472","article-title":"Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein","volume":"34","author":"Sorrentino","year":"2013","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.vph.2021.106878_bb0155","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/carcin\/bgx058","article-title":"Cholesterol uptake and regulation in high-grade and lethal prostate cancers","volume":"38","author":"Stopsack","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.vph.2021.106878_bb0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.biopha.2018.08.145","article-title":"Bergapten inhibits liver carcinogenesis by modulating LXR\/PI3K\/Akt and IDOL\/LDLR pathways","volume":"108","author":"Pattanayak","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"40","key":"10.1016\/j.vph.2021.106878_bb0165","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1038\/s41388-020-01439-0","article-title":"Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma","volume":"39","author":"Yang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.vph.2021.106878_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.10.898","article-title":"Regulation of intestinal LDLR by the LXR-IDOL axis","volume":"315","author":"van Loon","year":"2020","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.vph.2021.106878_bb0175","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.18632\/aging.101597","article-title":"IDOL in metabolic, neurodegenerative and cardiovascular disease","volume":"10","author":"van Loon","year":"2018","journal-title":"Aging (Albany NY)"},{"issue":"314","key":"10.1016\/j.vph.2021.106878_bb0180","doi-asserted-by":"crossref","first-page":"314ra184","DOI":"10.1126\/scitranslmed.aad1904","article-title":"The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis","volume":"7","author":"Choi","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.vph.2021.106878_bb0185","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cmet.2014.10.001","article-title":"The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice","volume":"20","author":"Hong","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.vph.2021.106878_bb0190","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pharmthera.2014.09.009","article-title":"Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine","volume":"146","author":"Fan","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.vph.2021.106878_bb0195","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jacl.2017.10.003","article-title":"Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin\/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children","volume":"12","author":"Girona","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.vph.2021.106878_bb0200","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00788-20","article-title":"Taurine-mediated IDOL contributes to resolution of Streptococcus uberis infection","volume":"89","author":"Wan","year":"2021","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.vph.2021.106878_bb0205","doi-asserted-by":"crossref","first-page":"19834","DOI":"10.1038\/s41598-020-76224-w","article-title":"Platycodin D enhances LDLR expression and LDL uptake via down-regulation of IDOL mRNA in hepatic cells","volume":"10","author":"Choi","year":"2020","journal-title":"Sci. Rep."},{"issue":"45","key":"10.1016\/j.vph.2021.106878_bb0210","doi-asserted-by":"crossref","first-page":"12651","DOI":"10.1021\/acs.jafc.0c05800","article-title":"Naringin alleviates atherosclerosis in ApoE(\u2212\/\u2212) mice by regulating cholesterol metabolism involved in gut microbiota remodeling","volume":"68","author":"Wang","year":"2020","journal-title":"J. Agric. Food Chem."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189121000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:20:09Z","timestamp":1761528009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189121000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":41,"alternative-id":["S1537189121000501"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2021.106878","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inducible degrader of LDLR: A potential novel therapeutic target and emerging treatment for hyperlipidemia","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2021.106878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106878"}}